ERIS Lifesciences Ltd share price logo

ERIS Lifesciences Ltd Share Price

(ERIS)

₹1417.350.85%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

ERIS Lifesciences Ltd Performance

  • Day's Low

    Day's High

    ₹1,388.4
    Day's Price Range
    ₹1,425
  • 52 Week's Low

    52 Week's High

    ₹815.85
    52-Week Price Range
    ₹1,593.9
1 Month Return+ 20.02 %
3 Month Return+ 2.37 %
1 Year Return+ 66.74 %
Previous Close₹1,405.45
Open₹1,405.00
Volume86.57K
Upper Circuit₹1,686.50
Lower Circuit₹1,124.40
Market Cap₹19,299.00Cr

ERIS Lifesciences Ltd Fundamentals

P/E Ratio

58.54

PEG Ratio

-13.94

Market Cap

₹19,299.00 Cr

P/B Ratio

4.53

EPS

29.19

Dividend Yield

0

Sector

Pharmaceuticals

ROE

12.63

ERIS Lifesciences Ltd Analyst Rating

based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts offering long term price targets for ERIS Lifesciences Ltd. An average target of ₹1509.22

Source: S&P Global Market Intelligence

ERIS Lifesciences Ltd Share analysis

ERIS Lifesciences Ltd price forecast by 9 analysts

Upside of6.48%

High

₹1700

Target

₹1509.22

Low

₹1270

ERIS Lifesciences Ltd target price ₹1509.22, a slight upside of 6.48% compared to current price of ₹1417.35. According to 9 analysts rating.

Source: S&P Global Market Intelligence

Key events for ERIS Lifesciences Ltd

  • Eris Lifesciences Sees Stock Surge and Investor Meeting - 20 Mar, 2025

    Eris Lifesciences Ltd experienced a 6.12% stock increase amid a significant volume surge. The company also scheduled an investor meeting with Mirae Asset for March 2025, emphasizing transparency and regulatory compliance.
  • Eris Lifesciences Restructures Holdings with Major Transfer - 07 Mar, 2025

    Eris Lifesciences has completed an internal restructuring by transferring its entire holdings in Eris Oaknet Healthcare and Aprica Healthcare to its subsidiary, Eris Therapeutics, for Rs 861.9 crore.
  • Eris Lifesciences Sells Stake, Appoints New President - 06 Mar, 2025

    Eris Lifesciences appointed Murari Ranganathan as President of Cardiometabolic Business and sold its entire stake in subsidiaries for Rs 861.9 crore, amid declining profits.

Insights on ERIS Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 18.47% to 18.72% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 8.01% to 8.35% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ERIS stock has moved up by 4.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ERIS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 129.8% return, outperforming this stock by 24.4%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 54.87% to 54.86% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 91.59 Cr → 83.63 Cr (in ₹), with an average decrease of 8.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 745.72 Cr → 731.67 Cr (in ₹), with an average decrease of 1.9% per quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 17.03% to 16.52% in Dec 2024 quarter

ERIS Lifesciences Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹483.48Cr (-)₹547.27Cr (↑13.19%)₹715.59Cr (↑30.76%)₹738.95Cr (↑3.26%)₹722.12Cr (↓2.28%)
Net Income₹101.46Cr (-)₹79.63Cr (↓21.52%)₹89.42Cr (↑12.29%)₹96.35Cr (↑7.75%)₹86.93Cr (↓9.78%)
Net Profit Margin20.99% (-)14.55% (↓30.68%)12.50% (↓14.09%)13.04% (↑4.32%)12.04% (↓7.67%)
Value in ₹ crore
Details2021202220232024
Total Assets₹1,855.34Cr (-)₹2,265.02Cr (↑22.08%)₹2,909.02Cr (↑28.43%)₹5,530.88Cr (↑90.13%)
Total Liabilities₹279.87Cr (-)₹346.47Cr (↑23.80%)₹687.13Cr (↑98.32%)₹3,006.86Cr (↑337.60%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹265.25Cr (-)₹395.41Cr (↑49.07%)₹369.41Cr (↓6.58%)₹322.33Cr (↓12.74%)₹336.29Cr (↑4.33%)

ERIS Lifesciences Ltd Index Inclusions

BSE Healthcare

₹41,421.50

-0.12 (-48.19%)

BSE 500

₹33,579.22

-0.39 (-132.39%)

S&P BSE 250 SmallCap

₹6,039.25

-0.45 (-27.45%)

Nifty Smallcap 250

₹15,104.05

-0.05 (-7.6%)

BSE Small-Cap

₹46,638.13

-0.35 (-165.52%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Nifty 500

₹21,339.55

-0.32 (-68.4%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (-36.15%)

S&P BSE 400 MidSmallCap

₹10,772.07

-0.52 (-56.71%)

ERIS Lifesciences Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
54.86%
-0.02
Foreign Institutions
8.35%
4.21
Mutual Funds
16.52%
-3.03
Retail Investors
18.72%
1.36
Others
1.55%
-3.87

ERIS Lifesciences Ltd Key Indicators

Details20202021202220232024
Earning Per Share (₹)21.8426.1629.8527.5129.19
Details20202021202220232024
Return On Equity %23.7224.3923.8819.2312.63
Details20202021202220232024
Return On Assets %19.0119.1417.9313.147.09
Details20202021202220232024
Book Value Per Share (₹)95.47116.1140.36161.48190.11

ERIS Lifesciences Ltd Valuation

ERIS Lifesciences Ltd in the last 5 years

  • Overview

  • Trends

Lowest (16.77x)

September 9, 2019

Industry (53.18x)

March 28, 2025

Today (58.54x)

March 28, 2025

Highest (61.09x)

February 7, 2025

LowHigh

ERIS Lifesciences Ltd Earnings and Dividends

  • ERIS Lifesciences Ltd Earnings Results

    ERIS Lifesciences Ltd’s net profit fell -18.6% since last year same period to ₹83.63Cr in the Q3 2024-2025. On a quarterly growth basis, ERIS Lifesciences Ltd has generated -8.69% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • ERIS Lifesciences Ltd Dividends February,2025

    In the quarter ending December 2024, ERIS Lifesciences Ltd has declared dividend of ₹7.35 - translating a dividend yield of 0.52%.

    Read More about Dividends

ERIS Lifesciences Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

ERIS Lifesciences Ltd is currently in a Bullish trading position according to technical analysis indicators.

ERIS Lifesciences Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹19,299.00 Cr56.12%0.75₹397 Cr₹2,056 Cr
NA₹104.50 Cr97.14%0.50NANA
NA₹6,790.80 Cr31.99%0.57₹216 Cr₹1,852 Cr
NA₹583.14 Cr71.28%0.56₹13 Cr₹154 Cr
NA₹401.61 Cr-7.88%0.54NANA

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated in 2007 and is engaged in manufacturing, distributing and marketing of branded pharmaceutical products, having presence in high growth chronic, sub-chronic and acute therapeutic areas. It has a portfolio of 112 Mother Brands across therapy areas and 5 subsidiaries, 4 of which are wholly owned subsidiaries. The company has made two acquisitions - UTH Healthcare Ltd for Rs 129 million for its product portfolio in 2017 and Indian branded formulations business Strides for Rs 5000 crore in 2017. It made its debut in secondary equity market in 2017 and in FY 2018 capital expenditure amounted to Rs 242.69 million and Rs 5061.52 million was paid towards business acquisition. In FY 2019 the company expanded its operations by constructing new softgel facility, extended facility for supplements and nutraceuticals, and added Zomelis products in its portfolio. In 2020, Kinedex became wholly owned subsidiary and the company launched new business divisions. In FY21 it launched Gluxit in SGLT2 segment, Eritel and LNBloc maintained ranks in their respective segments, developed Bricet and fortified portfolio with the launch of ZACD. In FY22 it acquired 100 stake in Oaknet Healthcare Ltd worth Rs 6500 million and launched human insulin through its subsidiary Eris M.J. Biopharm Ltd and Xsulin in vials and cartridges.

Revenue: ₹722.12Cr as on December 2024 (Q4 24)
Net Profit: ₹86.93Cr as on December 2024 (Q4 24)
Listing date: 29 Jun, 2017
Chairperson Name: Amit Indubhushan Bakshi
OrganisationERIS Lifesciences Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on ERIS Lifesciences Ltd

What is ERIS Lifesciences Ltd price today?

ERIS Lifesciences Ltd share price today stands at ₹1417.35, Open: ₹1405, Previous Close: ₹1405.45, High: ₹1425, Low: ₹1388.4, 52 Week High: ₹1593.9, 52 Week Low: ₹815.85.

How to Buy ERIS Lifesciences Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy ERIS Lifesciences Ltd shares

What are today's traded volumes of ERIS Lifesciences Ltd?

Today's traded volume of ERIS Lifesciences Ltd(ERIS) is 86.57K.

What is today's market capitalisation of ERIS Lifesciences Ltd?

Today's market capitalisation of ERIS Lifesciences Ltd(ERIS) is ₹19299Cr.

What is the 52 Week High and Low Range of ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd (ERIS)
Price
52 Week High
₹1593.9
52 Week Low
₹815.85

How much percentage ERIS Lifesciences Ltd is down from its 52 Week High?

ERIS Lifesciences Ltd (ERIS) share price is ₹1417.35. It is down -11.08% from its 52 Week High price of ₹1593.9

How much percentage ERIS Lifesciences Ltd is up from its 52 Week low?

ERIS Lifesciences Ltd (ERIS) share price is ₹1417.35. It is up 73.73% from its 52 Week Low price of ₹815.85